MHRA Largest Seizure of Unlicensed Weight Loss Medicines
Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.
2 SOPs may need review
FDA advises consumers not to purchase or use Tawon Liar due to undisclosed active ingredients including tapentadol, dexamethasone, and meloxicam.
Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.
Regulatory Intelligence Lead
as needed
Monitor for adverse events from unapproved drug ingredients.
FDA updated its public notification regarding Tawon Liar on May 29, 2026, adding detection of tapentadol, dexamethasone, and meloxicam. Previous notifications in 2023 and 2022 reported meloxicam, ketorolac, and dexamethasone.
The product contains undeclared active pharmaceutical ingredients, including a controlled opioid, an NSAID, and a corticosteroid, which can cause serious adverse reactions, drug interactions, and have abuse potential.
Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.
Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.
2 SOPs may need review
Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.
2 SOPs may need review
Ask the safety/device vigilance and PV CSV leads to: (1) confirm whether any marketed/fielded SaMD/AIaMD uses adaptive ML or planned updates that would fit a PCCP-like approach; (2) review current change-control SOPs and technical documentation to ensure change governance and transparency artifacts are captured and retrievable; (3) verify post-market/vigilance processes explicitly account for algorithm updates (e.g., monitoring after updates, escalation criteria).
5 SOPs may need review
Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.
2 SOPs may need review